In vitro activities of 3-hydroxy-1,5,6-trimethoxy-2-methyl-9,10-anthraquinone against non-small cell lung carcinoma.

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V6H 3Z6, Canada.
Archives of Pharmacal Research (Impact Factor: 1.54). 07/2012; 35(7):1251-8. DOI: 10.1007/s12272-012-0716-4
Source: PubMed

ABSTRACT Medicinal herbs are the preferred candidates for drug discovery against human diseases including cancer. The roots of Prismatomeris connata have been used in traditional herbal medicine to treat many health problems, particularly pneumoconiosis. This study was to test the anti-tumor activity of 3-Hydroxy-1,5,6-trimethoxy-2-methyl-9,10-anthraquinone (PCON6), a major anthraquinone derivative from C. connata, against lung cancer. Cell viability in cultures was assessed by MTT assay. Cell death or apoptosis was determined with Annexin-V and 7-Aminoactinomycin D staining. Cell cycle was analyzed by both propidium iodide DNA staining and BrdU incorporation assay. Here we showed that in a panel of fifteen different tumor cells lines, a group of four non-small cell lung carcinoma (NSCLC) cell lines exhibited a relatively higher sensitivity to PCON6 growth inhibition than the rest of most non-lung cancer cell lines (p = 0.0461). Further studies demonstrated that the suppression of NSCLC H520 cell growth by PCON6 was associated with its induction of apoptosis at 20 μM (p = 0.0008), and of cell accumulation at S phase cell cycle (p < 0.05) that was further supported by a decrease in cdc2 protein expression. This preliminary study suggests that natural compound PCON6 has relatively selective cytotoxicity against NSCLC growth and represent a concept of developing a novel drug therapy specific for NSCLC based on the roots of C. connata or PCON6.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Three new anthraquinones, 1-hydroxy-2,3-dimethoxy-7-methyl-9,10-anthraquinone, 1,3-dihydroxy-5,6-dimethoxy-2-methyl-9,10-anthraquinone, and 3-hydroxy-1,5,6-trimethoxy-2-methyl-9,10-anthraquinone, along with five known anthraquinones were isolated from the roots of Prismatomeris tetrandra. Their structures were determined on the basis of spectroscopic data.
    CHEMICAL & PHARMACEUTICAL BULLETIN 11/2005; 53(10):1330-2. · 1.56 Impact Factor
  • Current Opinion in Cell Biology 05/1990; 2(2):262-8. · 11.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study is to report the long-term outcome and secondary tumours of early breast cancer patients of adjuvant CNF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) chemotherapy. One hundred and ninety four patients, 185 primary early breast cancer and nine locoregionally recurrent breast cancer patients, were entered onto the trial between May 1986 and November 1993. The therapies included surgery, radiation therapy, adjuvant CNF chemotherapy, and tamoxifen according to hormonal status. Some of patients were treated twice with CMF (methotrexate). The median follow-up time was 12.9 years. Eighty nine (48%) primary breast cancers relapsed, and six locoregional breast cancers relapsed. After 5-10 years the relapse incidence decreased notably. Eighty three patients died of breast cancer, and nine of other causes. Two cases of leukemia, six cases of skin cancer, two cases of Hodgkin's disease, two cases of meningioma, and two cases of endometrial cancer were observed. This article confirms the feasibility of adjuvant CNF for early breast cancer patients. Questions of possible causability of secondary cancer have yet to be explored.
    Acta Oncologica 02/2008; 47(1):120-3. · 2.87 Impact Factor